Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q4 2023 Earnings Presentation
19 slides from Bactiguard Holding Ab's earnings presentation, Feb 8, 2024
Slide 1: Q4 and year-end 2023 presentation
Q4 and year-end 2023 presentation Thursday 8 February 2024 Thomas von Koch, Interim CEO Patrick Bach, CFO
Slide 2: Stable fourth quarter marking the end of a challenging year
Q4 and year-end 2023: Stable fourth quarter marking the end of a challenging year
Slide 3: Christine Lind appointed new CEO
Christine Lind appointed new CEO Broad strategic and operational experience from more than 25 years in the healthcare sector • CEO/executive level business development and strategy positions at biotech companies • Investment banker at Merrill Lynch in New York, advising biotech and pharma companies
Slide 4: Biggest strategic shift in Bactiguard's history – recap
Biggest strategic shift in Bactiguard’s history – recap Focus areas head – update on transformation progress License R&D and coating development BIP portfolio - strengthen organization - BD agreement - double down on - institutionalize - transition/phase out ongoing current partnerships - Billy Söde
Slide 5: Strengthened ties with BD in Q4 2023
Strengthened ties with BD in Q4 2023 Bactiguard’s longest and strongest partnership Looking back… • BD (Becton Dickinson & Company) one of the largest global medical technology companies • In partnership since early 1990s – more than 230 million coated Foley catheters sold to date generating more th
Slide 6: Zimmer Biomet
(& Zimmer BiOMET Sh patients implanted have not Sese.See ‘experienced infection’
Slide 7: Bactiguard technology does not impair bone integration
t ~ _ eS BACTIGUARD TECHNOLOGY Dy _ DOES NOT IMPAIR THE Wa BONE INTEGRATION
Slide 8: With Bactiguard
WITH BACTIGUARD
Slide 9: A license focused business model – recap
A license focused business model – recap Customer acquisition costs Revenue streams development partners transfer agreement Initial discussion Negotiations Prospects Material Application Exclusivity partners License partners development partners no products in market products in market Development E
Slide 10: Financials Q4 2023 (Q4 2022) and key events
Financials Q4 2023 (Q4 2022) and key events Stable fourth quarter marking the end of a challenging year Revenues EBITDA Net Loss Operating cash flow 61 (72) SEKm -4.2 (-1.1) SEKm -27.2 (-14.2) SEKm 4.1 (3.1) SEKm Key events in Q4 • Strengthened relationship with BD – interim agreement granting BD ex
Slide 11: Financial overview
Financial overview SEKm 2023 2022 2023 2022 • Recurring License sales from BD of Oct-Dec Oct-Dec Full year Full year SEK 93.1 million FY sales vs SEK 133.9 million LY, related to the stock reduction Total revenues 61.3 72.2 223.2 253.5 • Recurring License revenues from - License 32.2 46.3 117.2 161.
Slide 12: Rolling 12-months
Rolling 12-months R12M Revenues and EBITDA in SEK million Recurring license revenues 250 80 • Key driver BD and initial 60 contributions from Zimmer 200 40 Biomet (trauma) 20 150 0 Non-recurring license revenues 100 -20 • Zimmer Biomet (broader 50 -40 portfolio) -60 0 -80 BPP sales • BIP end of life
Slide 13: Q4 2023 highlights – Licensing business
Q4 2023 highlights – Licensing business Recurring license revenue Non-recurring license revenue Revenues Q4 2023 Revenues Q4 2023 29.1 (38.9) SEKm 3.0 (7.4) SEKm Orthopedics (trauma) Orthopedics (broader portfolio) • BD exclusive global license for Bactiguard • ZNN Bactiguard roll-out across • Exclu
Slide 14: Q4 2023 highlights and status – BPP
Q4 2023 highlights and status – BPP BPP (Bactiguard Product Portfolio) Revenues Q4 2023 24.1 (14.9) SEKm 61% • BPP FY sales of 84 million SEK, up 36 percent vs LY, partly attributable to the “end-of-life” BIP products sales in Q4 • Wound Management account for SEK 54 million of the BPP full-year 202
Slide 15: Updated financial targets – recap
Updated financial targets – recap Mid-term expectations given new strategy and license focused business model Application areas Profitability Growth generating revenues have at least 10 application areas deliver an EBITDA of SEK 500 deliver net sales in excess of in license partnerships with million
Slide 16: Why avoiding biofilm matters
Why avoiding biofilm matters After a few hours • Medical devices attract microbes After a few seconds After a few days • Bacteria multiply on the surface, colonize and start spreading • Within days, biofilm forms protecting them from immune responses and antibiotics • Established biofilm a source fo
Slide 17: Opportunities behind critical global healthcare trends
Opportunities behind critical global healthcare trends The issues The USD 80bn market opportunity • Antimicrobial resistance one of the top global public Orthopedics 40 health threats facing humanity – associated with the death of close to 5 million people globally in 2019 Urology 3 • 1 in 10 patien
Slide 18: Q&A
Q&A Q&A to champion a healthier world by preventing infections 18
Slide 19: Questions & Answers
Questions & Answers Q4 and year-end 2023 presentation Thomas von Koch Patrick Bach Interim CEO CFO 19